LivaNova
LIVN | NASDAQ
$92.44
+$1.12 (+1.23%)
At close: Nov 16, 2026, 4:00 PM ET
$92.44
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
LivaNova Company Profile
Company profile explainedCompany Profile
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Key Executives
| Name | Position |
|---|---|
| Vladimir A. Makatsaria | Chief Executive Officer & Director |
| Alex Shvartsburg | Chief Financial Officer |
| Anne Liddy | Chief Legal Officer |
| Ahmet Tezel | Chief Innovation Officer |
| Briana Gotlin | Vice President of Investor Relations |
| Deanna Wilke | Vice President of Corporate Communications |
| Lindsey Little | VP & Chief Accounting Officer |
| Natalia Sergeyevna Kozmina | Chief Human Resources Officer |
| Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement |
| Philip Kowalczyk | Chief Strategy & Corporate Development Officer |
| Sarah Mohr | VP of Legal & Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2026 | 4 | Filing |
| Sep 14, 2026 | 4 | Filing |
| Sep 08, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 3 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 06, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 05, 2026 | IRANNOTICE | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 3 | Filing |
LivaNova
| Country | United Kingdom |
| IPO Date | Oct 19, 2015 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 3,300 |
| CEO | Vladimir A. Makatsaria |
Contact Details
5220 Valiant Court Gloucester,
GL GL3 4FE United Kingdom
Stock Details
| Ticker Symbol | LIVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001639691 |
| CUSIP Number | G5509L101 |
| ISIN Number | GB00BYMT0J19 |
| SIC Code | 3845 |
Recent News
- 4 days ago / seekingalpha.comLivaNova: Paying Off The Last Legacy Bill Just As The Sleep Apnea Market Opens Up
- 8 days ago / seekingalpha.comLivaNova PLC (LIVN) Presents at 2026 UBS Global Healthcare Conference Transcript
- 13 days ago / seekingalpha.comLivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
- 13 days ago / marketbeat.comLivaNova Q3 Earnings Call Highlights
- 13 days ago / zacks.comLivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say
- 13 days ago / zacks.comLivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates
- 13 days ago / businesswire.comLivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- 25 days ago / businesswire.comNeuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
- 2 months ago / seekingalpha.comLivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / fool.comLivaNova Director Sells 1,650 Shares for $131,500
Add to Watchlist
Select watchlists to add or remove LIVN